Binge eating Disorder Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Antidepressants, Anticonvulsants, Stimulants, Others), By Distribution Channel (Offline, Online), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 708.15 MIllion
CAGR (2026-2031)	7.21%
Fastest Growing Segment	Antidepressants
Largest Market	North America
Market Size (2031)	USD 1075.32 MIllion

Market Overview

The Global Binge eating Disorder Treatment Market will grow from USD 708.15 MIllion in 2025 to USD 1075.32 MIllion by 2031 at a 7.21% CAGR. The Global Binge Eating Disorder Treatment Market comprises a spectrum of pharmacotherapeutic agents and evidence-based psychotherapies designed to mitigate compulsive overeating episodes and address underlying psychological comorbidities. The primary drivers fueling market expansion include the escalating global incidence of eating disorders and a marked increase in diagnostic rates stemming from improved mental health awareness. Furthermore, the regulatory approval of targeted central nervous system stimulants continues to broaden the therapeutic landscape for clinicians. According to the Alliance for Eating Disorders, in 2024, Binge Eating Disorder was identified as the most common eating disorder among adults in the United States, affecting three times the number of individuals diagnosed with Anorexia Nervosa and Bulimia Nervosa combined.

Despite these strong growth factors, the market faces a significant impediment regarding the high cost of specialized treatment and inadequate insurance reimbursement coverage which restricts widespread patient accessibility. This financial barrier is particularly acute in developing regions where mental health infrastructure remains underfunded and creates a substantial gap between the addressable patient population and those receiving effective care. Consequently, the lack of affordable therapeutic options could severely limit the potential revenue realization for manufacturers in price-sensitive international markets.

Key Market Drivers

Robust Clinical Pipeline and Drug Development Activities serve as a primary engine for market growth, characterized by a shift towards novel mechanisms of action beyond traditional stimulants. Pharmaceutical companies are aggressively advancing late-stage trials to address the scarcity of FDA-approved therapies, thereby attracting significant investment into the sector. A notable development occurred when Axsome Therapeutics announced in April 2024, in a corporate press release, the initiation of the ENGAGE Phase 3 trial to evaluate solriamfetol, a dopamine and norepinephrine reuptake inhibitor, for treating adults with Binge Eating Disorder. This surge in clinical activity extends to alternative therapeutic classes, including psychedelic-assisted treatments which are gaining regulatory traction. According to Tryptamine Therapeutics, November 2024, in an official clinical update, the company completed subject dosing in a Phase 1b clinical trial for TRP-8803, an IV-infused psilocin formulation, highlighting the diversification of the developmental landscape beyond standard pharmacotherapy.

Favorable Government Initiatives and Reimbursement Policies are equally critical in driving market accessibility and validating the medical necessity of treatment. Legislative bodies are increasingly allocating funds to bridge the gap between diagnosis and effective care, particularly within underserved primary care settings where early detection is pivotal. This commitment is evident in federal budget allocations designed to enhance provider competency and infrastructure. According to the Eating Disorders Coalition, April 2024, in the 'Eating Disorders Victories in Congress' Fiscal Year 2024 Funding Package' report, the organization secured $1 million specifically for training primary health care providers on eating disorders screening, brief intervention, and referral to treatment (SBIRT). Such policy milestones not only destigmatize the condition but also incentivize healthcare systems to integrate specialized BED therapies, ultimately expanding the commercial reach for treatment providers globally.

Download Free Sample Report

Key Market Challenges

The high cost of specialized treatment and inadequate insurance reimbursement coverage constitute a significant barrier to the expansion of the Global Binge Eating Disorder Treatment Market. This economic impediment restricts patient access to necessary pharmacotherapeutic agents and evidence-based psychotherapies, effectively reducing the addressable market size. When patients face prohibitive out-of-pocket expenses and insurance policies fail to provide comprehensive coverage for long-term care, diagnostic rates do not translate into treated cases. This disconnect severely limits revenue realization for pharmaceutical manufacturers and healthcare providers, particularly in regions where public health funding is insufficient to bridge the financial gap.

The magnitude of this financial burden is substantial. According to the Butterfly Foundation, in 2024, the total economic and social cost of eating disorders in Australia alone was estimated at $66.9 billion, with the average cost per person reaching approximately $60,654. Such high individual costs highlight the affordability crisis that prevents a large segment of the diagnosed population from accessing consistent care. Consequently, these financial barriers hampers the market's ability to capitalize on rising diagnostic trends, stalling growth in both developed and price-sensitive international regions.

Key Market Trends

Integration of Digital Therapeutics and Mobile Health Apps is fundamentally reshaping the market by dismantling geographical and logistical barriers to effective care. Virtual-first care models are gaining significant traction and investor confidence, validating the shift toward remote, scalable interventions that complement traditional therapy for Binge Eating Disorder. This digital expansion allows providers to reach underserved patient populations and deliver evidence-based treatments directly to patients' homes, bypassing the capacity constraints of physical facilities. According to Behavioral Health Business, August 2025, in the article 'Digital Eating Disorder Treatment Company Equip Health Discloses $47M Fundraise', virtual provider Equip Health secured nearly $47 million in new equity funding to address the rising demand for accessible, technology-enabled remote care.

Strategic Consolidation of Specialized Treatment Centers is simultaneously occurring as major behavioral health networks optimize their portfolios to emphasize clinical quality and operational efficiency. In a competitive landscape, these consolidated entities are prioritizing rigorous data collection to demonstrate treatment efficacy, thereby securing payer reimbursement and validating their care models against fragmented competitors. Large-scale providers are increasingly leveraging network-wide outcome data to substantiate the value of their residential and outpatient protocols. According to Odyssey Behavioral Healthcare, October 2025, in the '2024 Treatment Outcomes Report', adults in the network's residential eating disorder programs achieved a 51% overall reduction in symptoms, underscoring the clinical value driven by these specialized, consolidated systems.

Segmental Insights

The Antidepressants segment is experiencing rapid expansion in the Global Binge Eating Disorder Treatment Market due to the high prevalence of psychiatric comorbidities, such as depression and anxiety, among diagnosed patients. Healthcare providers frequently prescribe Selective Serotonin Reuptake Inhibitors to manage these concurrent mental health conditions, thereby indirectly addressing binge eating behaviors. Furthermore, the widespread availability and affordability of generic antidepressants facilitate their adoption over highly regulated stimulants. This trend is supported by clinical practices favoring non-addictive pharmacotherapies for patients with a history of substance misuse or those requiring long-term maintenance.

Regional Insights

North America maintains a dominant position in the Global Binge Eating Disorder Treatment Market, primarily driven by high disease awareness and a robust diagnostic framework. The region benefits from a well-established healthcare sector that facilitates early intervention and access to approved therapies. A significant market driver is the regulatory landscape, notably the U.S. Food and Drug Administration's (FDA) approval of lisdexamfetamine dimesylate as the first medication specifically for this condition. Furthermore, initiatives by organizations such as the Substance Abuse and Mental Health Services Administration (SAMHSA) actively promote mental health resources, fostering a supportive environment for treatment adoption.

Recent Developments

• In September 2025, Novo Nordisk A/S presented new clinical data at the European Association for the Study of Diabetes (EASD) Annual Meeting, focusing on the broader effects of its GLP-1 receptor agonist, semaglutide. The company shared findings related to the reduction of "food noise"—intrusive thoughts about food—and improved control of eating in individuals with obesity and related comorbidities. These metrics are critical components in the management of binge eating disorder, suggesting that the medication’s mechanism of action could address the underlying behavioral drivers of the condition beyond weight loss alone.
• In September 2025, Eli Lilly and Company detailed plans for a randomized clinical trial to directly compare its drug tirzepatide against lisdexamfetamine dimesylate, the only currently approved medication for binge eating disorder. The study was designed to assess the efficacy and safety of tirzepatide in adults with obesity and moderate-to-severe binge eating disorder, aiming to determine if the dual GIP/GLP-1 receptor agonist could provide superior symptom reduction compared to the standard of care. This head-to-head trial represented a significant step in potentially expanding the indicated uses of the company's incretin-based therapies.
• In April 2025, Tryptamine Therapeutics Ltd entered into a landmark clinical trial research agreement with Swinburne University of Technology to advance the development of its lead program for binge eating disorder. This collaboration marked the launch of the world’s first clinical trial investigating the use of intravenous psilocin, a psychedelic compound, specifically for this indication. The study aimed to evaluate the safety and efficacy of the company's proprietary formulation, TRP-8803, in conjunction with psychotherapy, offering a potential new therapeutic modality for patients who have not responded to existing treatments.
• In March 2024, Tonix Pharmaceuticals Holding Corp. presented data regarding its central nervous system portfolio at the American Chemical Society Spring 2024 Meeting. During the event, the company highlighted its ongoing Phase 2 'STROBE' study, which investigated the efficacy and safety of TNX-1900 (intranasal potentiated oxytocin) for the treatment of binge eating disorder in adults. The presentation also detailed the discovery of novel oxytocin analogues designed to treat excessive eating conditions, including binge eating behavior. These developments underscored the company's continued focus on addressing the lack of effective non-stimulant pharmacological options for patients suffering from this condition.

Key Market Players

• Viatris Inc.
• Johnson & Johnson Services, Inc.
• Lupin Ltd.
• Omeros Corp.
• Pyramid Healthcare Inc.
• Sumitomo Pharma Co. Ltd.
• Takeda Pharmaceutical Co. Ltd.
• Eli Lilly and Co
• Tonix Pharmaceuticals Holding Corp.
• Tryp Therapeutics Inc

By Type	By Distribution Channel	By Region
Antidepressants Anticonvulsants Stimulants Others	Offline Online	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Binge eating Disorder Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Binge eating Disorder Treatment Market, By Type:

• Antidepressants
• Anticonvulsants
• Stimulants
• Others

• Binge eating Disorder Treatment Market, By Distribution Channel:

• Offline
• Online

• Binge eating Disorder Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE